Key Points
- CEO Keith Sullivan sold 8,452 shares on Feb. 26 at an average price of $1.35 for roughly $11,410, trimming his stake by 0.55% to 1,524,713 shares (≈$2.06M).
- STIM traded at $1.34 (down $0.08) with about 1.0M shares changing hands; the company has a market cap of ≈$91.8M, a negative P/E, and a 52‑week range of $1.20–$5.92 (50‑day / 200‑day MAs: $1.66 / $2.25).
- Institutional investors own about 53.6% of the stock with notable stake increases from UBS and Vanguard, and analyst coverage is mixed — average rating "Hold" with a $7.00 average price target (one Buy, one Sell).
Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) CEO Keith Sullivan sold 8,452 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $1.35, for a total value of $11,410.20. Following the sale, the chief executive officer directly owned 1,524,713 shares of the company's stock, valued at approximately $2,058,362.55. This represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Neuronetics Stock Performance
Shares of STIM stock traded down $0.08 during trading hours on Friday, reaching $1.34. 1,000,583 shares of the company's stock were exchanged, compared to its average volume of 2,941,062. The company has a debt-to-equity ratio of 2.09, a current ratio of 2.24 and a quick ratio of 2.09. The company's 50 day moving average is $1.66 and its two-hundred day moving average is $2.25. The company has a market cap of $91.78 million, a P/E ratio of -1.63 and a beta of 0.79. Neuronetics, Inc. has a 1 year low of $1.20 and a 1 year high of $5.92.
Institutional Investors Weigh In On Neuronetics
Institutional investors and hedge funds have recently made changes to their positions in the company. AdvisorShares Investments LLC lifted its stake in Neuronetics by 8.3% during the second quarter. AdvisorShares Investments LLC now owns 130,534 shares of the company's stock valued at $456,000 after buying an additional 10,000 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its holdings in shares of Neuronetics by 436.2% during the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 86,919 shares of the company's stock valued at $303,000 after acquiring an additional 70,709 shares during the period. Squarepoint Ops LLC lifted its position in shares of Neuronetics by 20.0% in the 3rd quarter. Squarepoint Ops LLC now owns 62,458 shares of the company's stock valued at $171,000 after acquiring an additional 10,423 shares in the last quarter. UBS Group AG boosted its stake in Neuronetics by 580.7% in the 3rd quarter. UBS Group AG now owns 2,164,831 shares of the company's stock worth $5,910,000 after purchasing an additional 1,846,801 shares during the period. Finally, Vanguard Group Inc. grew its position in Neuronetics by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,832,118 shares of the company's stock worth $7,732,000 after purchasing an additional 89,504 shares in the last quarter. 53.59% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the stock. Wall Street Zen raised shares of Neuronetics from a "sell" rating to a "hold" rating in a report on Saturday, December 6th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Neuronetics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $7.00.
View Our Latest Stock Report on STIM
Neuronetics Company Profile
(
Get Free Report)
Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company's flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.
Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
